Mechanisms of cutaneous toxicities to EGFR inhibitors

Nature Reviews Cancer

Volumn 6, Issue 10, 2006, Pages 803-812

  Lacouture, Mario E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CELECOXIB; CETUXIMAB; CORTICOSTEROID; CYCLOSPORIN DERIVATIVE; DOXYCYCLINE; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; LACTIC ACID; LIDOCAINE; PANITUMUMAB; PIMECROLIMUS; PRAMOCAINE; SALICYLIC ACID; TACROLIMUS; TETRACYCLINE DERIVATIVE; UREA;

ALOPECIA; ATOPIC DERMATITIS; BURNING SENSATION; CANCER STAGING; COMEDO; CONFERENCE PAPER; DRY SKIN; FLUSHING; HAIR LOSS; HEMATOPOIETIC SYSTEM; HUMAN; HYPERTRICHOSIS; NAIL DISEASE; NONHUMAN; PARAKERATOSIS; PARONYCHIA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RASH; ROSACEA; SENSORY DYSFUNCTION; SIGNAL TRANSDUCTION; SKIN APPENDAGE DISEASE; SKIN EDEMA; SKIN FRAGILITY; SKIN INFLAMMATION; SKIN TOXICITY; TELANGIECTASIA; TRICHOMEGALY; XEROSIS;

ANTIBODIES, MONOCLONAL; ENZYME INHIBITORS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN DISEASES;

EID: 33749018219     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1970     Document Type: Conference Paper

References (84)

1. Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341-354 (2005).
2. Dancey, J. & Sausville, E. A. Issues and progress with protein kinase inhibitors for cancer treatment. Nature Rev. Drug Discov. 2, 296-313 (2003).
3. Molinari, E. et al. Cetuximab-induced acne. Dermatology. 211, 330-333 (2005).
4. Perez-Soler, R. & Saltz, L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 23, 5235-5246 (2005). The relationship between cutaneous toxicity and clinical outcome has been shown in several studies, indicating that higher doses result in greater response. Therefore, an improved examination of rash during trials is encouraged.
5. Robert, C. et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 6, 491-500 (2005).
6. Jost, M., Kari, C. & Rodeck, U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 10, 505-510 (2000).
7. OSI Pharmaceuticals. Tarceva package insert (2005).
8. ImClone Systems. Erbitux package insert (2006).
9. Mendelsohn, J. & Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799 (2003).
10. Kari, C. et al. Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res. 63, 1-5 (2003).
11. Fuchs, E. & Raghavan S. Getting under the skin of epidermal morphogenesis. Nature Rev. Genet. 3, 199-209 (2002).
12. Candi, E., Schmidt, R. & Melino G. The cornified envelope: a model of cell death in the skin. Nature Rev. Mol. Cell Biol. 6, 328-340 (2005).
13. Nanney, L. B., Stoscheck, C. M., King, L. E. Jr, Underwood, R. A. & Holbrook, K. A. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J. Invest. Dermatol. 94, 742-748 (1990).
14. Miettinen, P. J. et al. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 376, 337-341 (1995).
15. Murillas, R. et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J. 14, 5216-5223 (1995).
16. Pasonen-Seppanen, S. et al. EGF upregulates, whereas TGF-β downregulates, the hyaluronan synthases Has2 and Has3 in organotypic keratinocyte cultures: correlations with epidermal proliferation and differentiation. J. Invest. Dermatol. 120, 1038-1044 (2003).
17. Peus, D., Hamacher, L. & Pittelkow, MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J. Invest. Dermatol. 109, 751-756 (1997).
18. Kobayashi, T., Hashimoto, K., Okumura, H., Asada, H. & Yoshikawa K. Endogenous EGF-family growth factors are necessary for the progression from the G1 to S phase in human keratinocytes. J. Invest. Dermatol. 111, 616-620 (1998).
19. L. Oncogene 16, 1493-1499 (1998).
20. Rodeck, U. et al. EGF-R-dependent regulation of keratinocyte survival. J. Cell Sci. 110, 113-121 (1997).
21. Woodworth, C. D. et al. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol. Cancer Ther. 4, 650-658 (2005).
22. Mimeault, M., Bonenfant, D. & Batra, S. K. New advances on the functions of epidermal growth factor receptor and ceramides in skin cell differentiation, disorders and cancers. Skin Pharmacol. Physiol. 17, 153-166 (2004).
23. Sayama, K. et al. Apoptosis signal-regulating kinase 1 (ASK1) is an intracellular inducer of keratinocyte differentiation. J. Biol. Chem. 276, 999-1004 (2001).
24. Threadgill, D. W. et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science 269, 230-234 (1995).
25. Hauser, P. J., Agrawal, D., Hackney, J. & Pledger, W. J. STAT3 activation accompanies keratinocyte differentiation. Cell. Growth Differ. 9, 847-855 (1998).
26. Levy, D. E. & Darnell, J. E. Jr. Stats: transcriptional control and biological impact. Nature Rev. Mol. Cell Biol. 3, 651-662 (2002).
27. Lorch, J. H. et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J. Biol. Chem. 279, 37191-37200 (2004).
28. Mascia, F., Mariani, V., Girolomoni, G. & Pastore, S. Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163, 303-312 (2003). Inhibition of EGFR tyrosine kinase activity results in upregulation of chemokines that recruit monocytes and dendritic cells. Mice that have been treated with an EGFRI show a greater hypersensitivity response to a skin irritant.
29. Pastore, S. et al. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J. Immunol. 174, 5047-5056 (2005).
30. Vallbohmer, D. et al. Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 23, 3536-3544 (2005).
31. Higgins, B. et al. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15, 503-512 (2004). Nude mice that were treated with the low-molecular-weight EGFRI erlotinib developed skin lesions with scabs and inflammatory cells, implicating keratinocyte effects as an important event.
32. Gibson, T. B., Ranganatha, A. & Grothey, A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer 6, 29-31 (2006).
33. Fisher, G. J. et al. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 379, 335-339 (1996).
34. El-Abaseri, T. B., Putta, S. & Hansen, L. A. Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis 27, 225-231 (2006).
35. L expression. J. Investig. Dermatol. 116, 860-866 (2001).
36. Jacot, W. et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br. J. Dermatol. 151, 238-241 (2004).
37. Sartor, C. I. Mechanisms of disease: radiosensitization by epidermal growth factor receptor inhibitors. Nature Clin. Pract. Oncol. 1, 80-87 (2004).
38. Mitra, S. S. & Simcock, R. Erlotinib induced skin rash spares skin in previous radiotherapy field. J. Clin. Oncol. 24, e28-e29 (2006).
39. Hymes, S. R., Strom, E. & Fife, C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J. Am. Acad. Dermatol. 54, 28-46 (2006).
40. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
41. Albanell, J. et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20, 110-124 (2002). Examination of skin in patients who were treated with an EGFRI showed morphological abnormalities, the expression of markers that indicate growth inhibition and altered differentiation.
42. Herbst, R. S. et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 20, 3815-3825 (2002).
43. Baselga, J. et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20, 4292-4302 (2002).
44. Malik, S. N. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin. Cancer Res. 9, 2478-2486 (2003).
45. Tan, A. R., Yang, X. & Hewitt, S. M. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Clin. Oncol. 22, 3080-3090 (2004).
46. KIP1 independent of MAPK activity. J. Biol. Chem. 275, 6987-6995 (2000).
47. Wakita, H. & Takigawa M. Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J. Biol. Chem. 274, 37285-37291 (1999).
48. Sano, S. et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nature Med. 11, 43-49 (2005).
49. Hofmeister, C. C. et al. Graft-versus-host disease of the skin: life and death on the epidermal edge. Biol. Blood Marrow Transplant. 10, 366-372 (2004).
50. Chave, T. A., Mortimer, N. J., Sladden, M. J., Hall, A. P. & Hutchinson, P. E. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br. J. Dermatol. 153, 241-253 (2005).
51. Van Doorn, R., Kirtschig, G., Scheffer, E., Stoof, T. J. & Giaccone, G. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br. J. Dermatol. 147, 598-601 (2002).
52. Busam, K. J. et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. 144, 1169-1176 (2001).
53. Pascual, J. C., Belinchon, I., Sivera, F. & Yuste, A. Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br. J. Dermatol. 153, 1222-1223 (2005).
54. Treudler, R. & Zouboulis, C. C. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures. Int. J. Dermatol. 44, 167-168 (2005).
55. Chang, G. C. et al. Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 4646-4648 (2004).
56. Fernandez-Galar, M., Espana, A. & Lopez-Picazo, J. M. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin. Exp. Dermatol. 29, 138-140 (2004).
57. Sergi, C., Kahl, P. & Otto, H. F. Immunohistochemical localization of transforming growth factor-α and epithelial growth factor receptor in human fetal developing skin, psoriasis and restrictive dermopathy. Pathol. Oncol. Res. 6, 250-255 (2000).
58. Tavakkol, A., Varani, J., Elder, J. T. & Zouboulis, C. C. Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor. Arch. Dermatol. Res. 291, 643-651 (1999).
59. Philpott M. P. & Kealey T. Effects of EGF on the morphology and patterns of DNA synthesis in isolated human hair follicles. J. Invest. Dermatol. 102, 186-191 (1994).
60. Fish, E. N., Ghislain, J., Trogadis, J. & Stevens, J. K. Inhibitory effects of α-interferon on epidermal growth factor-mediated receptor-dependent events. Cancer Res. 53, 5148-5157 (1993).
61. Graves, J. E., Jones, B. F., Lind, A. C. & Heffernan, M. P. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J. Am. Acad. Dermatol. 55, 349-353 (2006).
62. Mak, K. K. & Chan, S. Y. Epidermal growth factor as a biologic switch in hair growth cycle. J. Biol. Chem. 278, 26120-26126 (2003).
63. Hansen L. A. et al. Genetically null mice reveal a central role for epidermal growth factor receptor in the differentiation of the hair follicle and normal hair development. Am. J. Pathol. 150, 1959-1975 (1997).
64. Westgate G. E., Craggs R. I. & Gibson W. T. Immune privilege in hair growth. J. Invest. Dermatol. 97, 417-420 (1991).
65. Heck D., E., Laskin D., L., Gardner C., R. & Laskin J., D. Epidermal growth factor suppresses nitric oxide and hydrogen peroxide production by keratinocytes: potential role for nitric oxide in the regulation of wound healing. J. Biol. Chem. 267, 21277-21280 (1992).
66. Nakano, J. & Nakamura, M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Dermatol. 30, 261-262 (2003)
67. Dainichi, T., Tanaka, M., Tsuruta, N., Furue, M. & Noda, K. Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor. Dermatology 207, 324-325 (2003).
68. Baran R. Etretinate and the nails (study of 130 cases) possible mechanisms of some side-effects. Clin. Exp. Dermatol. 11, 148-152 (1986).
69. Rhee, J., Oishi, K., Garey, J. & Kim, E. Management of rash and other toxicities in patients treated with epidermal growth factor receptor-targeted agents. Clin. Colorectal Cancer 5, S101-S106 (2005).
70. Perez-Soler, R. et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 10, 345-356 (2005). A group of experts who study the EGFRI-induced rash indicate the importance of the rash in treated patients and make rational recommendations for its management.
71. Jost, M., Huggett, T. M., Kari, C. & Rodeck, U. Matrix-independent survival of human keratinocytes through an EGF receptor/MAPK-kinase-dependent pathway. Mol. Biol. Cell 12, 1519-1527 (2001).
72. Lopez-Ilasaca, M. et al. Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J. Biol. Chem. 273, 9430-9434 (1998).
73. Perez-Soler, R., Zou, Y., Li, T., Tornos, C. & Ling, Y. Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. J. Clin. Oncol. 24, 3036 (2006).
74. Gutzmer, R., Werfel, T., Mao, R., Kapp, A. & Elsner, J. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br. J. Dermatol. 153, 849-851 (2005).
75. Segaert, S. & Van Cutsem, E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 16, 1425-1433 (2005).
76. Sapadin, A. N. & Fleischmajer, R. Tetracyclines: nonantibiotic properties and their clinical implications. J. Am. Acad. Dermatol. 54, 258-265 (2006).
77. Onoda, T., Ono, T., Dhar, D. K., Yamanoi, A. & Nagasue N. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int. J. Cancer 118, 1309-1315 (2006).
78. Fox, L. P. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy. Oncology 20, 26-34 (2006).
79. Laux, I., Jain, A., Singh, S. & Agus, D. B. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer 94, 85-92 (2006).
80. Perea, S. et al. Genotypic bases of EGFR inhibitors pharmacological actions. J. Clin. Oncol. 22, 3005 (2004).
81. Hidalgo, M. et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001).
82. Lenz, H. J. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 20, 5-13 (2006).
83. Lacouture, M. E., Basti, S., Patel, J. & Benson A. The SERIES Clinic: an interdisciplinary approach to the management of toxicities to EGFR inhibitors. J. Support. Oncol. 4, 236-238 (2006). A novel interdisciplinary approach to the management of EGFR-inhibitor skin toxicities is proposed, using a patient case as a model. Early intervention and close follow-up are key strategies to prevent alterations in the anticancer agent.
84. Tullo, A. B. et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye 19, 729-738 (2005).